Long COVID: what do we know now and what are the challenges ahead?

Snehal M Pinto Pereira; Fiona Newlands; Jake Anders; Amitava Banerjee; Sarah Beale; Ann Blandford; Kate Brown; Feifei Bu; Wing Lam Erica Fong; Gina Gilpin; Pia Hardelid; Jana Kovar; Jason Lim; Chloe Park; Vishnuga Raveendran; Anoop D Shah; Xin Shao; Andrew Wong; Terence Stephenson; Roz Shafran

doi:10.1177/01410768241262661

Long COVID: what do we know now and what are the challenges ahead?

Snehal M Pinto Pereira, Fiona Newlands, Jake Anders, Amitava Banerjee, Sarah Beale, Ann Blandford, Kate Brown, Feifei Bu, Wing Lam Erica Fong, Gina Gilpin, Pia Hardelid, Jana Kovar, Jason Lim, Chloe Park, Vishnuga Raveendran, Anoop D Shah, Xin Shao, Andrew Wong, Terence Stephenson, Roz Shafran

School of Applied Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

The first case of severe acute respiratory syndrome coronavirus 2 was reported in Wuhan, China, in December 2019; the first case in the UK was reported in January 2020. By March 2020, reports were emerging that some coronavirus disease 2019 (COVID-19) survivors were left with persisting health problems rather than making a complete recovery. These people are commonly referred to as having Long COVID or post-COVID-19 condition. The UK government has invested over £50 million in Long COVID research1 and over 200 symptoms associated with Long COVID, in adults and in children and young people (CYP), have been identified.2,3 Yet, there is stark heterogeneity in the literature regarding the implementation of, and approach to, treating Long COVID. The purpose of this commentary is to reflect on what we know and what we need to know about Long COVID and to provide a springboard for suggestions on how to be better prepared for future pandemics.

Original language	English
Pages (from-to)	224-228
Number of pages	5
Journal	Journal of the Royal Society of Medicine
Volume	117
Issue number	7
DOIs	https://doi.org/10.1177/01410768241262661
Publication status	Published - 30 Jul 2024

Access to Document

10.1177/01410768241262661Licence: CC BY

Cite this

Pereira, S. M. P., Newlands, F., Anders, J., Banerjee, A., Beale, S., Blandford, A., Brown, K., Bu, F., Fong, W. L. E., Gilpin, G., Hardelid, P., Kovar, J., Lim, J., Park, C., Raveendran, V., Shah, A. D., Shao, X., Wong, A., Stephenson, T., & Shafran, R. (2024). Long COVID: what do we know now and what are the challenges ahead? Journal of the Royal Society of Medicine, 117(7), 224-228. https://doi.org/10.1177/01410768241262661

@article{c98c3d20b0944895b545d29c683edfbf,

title = "Long COVID: what do we know now and what are the challenges ahead?",

abstract = "The first case of severe acute respiratory syndrome coronavirus 2 was reported in Wuhan, China, in December 2019; the first case in the UK was reported in January 2020. By March 2020, reports were emerging that some coronavirus disease 2019 (COVID-19) survivors were left with persisting health problems rather than making a complete recovery. These people are commonly referred to as having Long COVID or post-COVID-19 condition. The UK government has invested over £50 million in Long COVID research1 and over 200 symptoms associated with Long COVID, in adults and in children and young people (CYP), have been identified.2,3 Yet, there is stark heterogeneity in the literature regarding the implementation of, and approach to, treating Long COVID. The purpose of this commentary is to reflect on what we know and what we need to know about Long COVID and to provide a springboard for suggestions on how to be better prepared for future pandemics.",

author = "Pereira, {Snehal M Pinto} and Fiona Newlands and Jake Anders and Amitava Banerjee and Sarah Beale and Ann Blandford and Kate Brown and Feifei Bu and Fong, {Wing Lam Erica} and Gina Gilpin and Pia Hardelid and Jana Kovar and Jason Lim and Chloe Park and Vishnuga Raveendran and Shah, {Anoop D} and Xin Shao and Andrew Wong and Terence Stephenson and Roz Shafran",

year = "2024",

month = jul,

day = "30",

doi = "10.1177/01410768241262661",

language = "English",

volume = "117",

pages = "224--228",

number = "7",

}

Pereira, SMP, Newlands, F, Anders, J, Banerjee, A, Beale, S, Blandford, A, Brown, K, Bu, F, Fong, WLE, Gilpin, G, Hardelid, P, Kovar, J, Lim, J, Park, C, Raveendran, V, Shah, AD, Shao, X, Wong, A, Stephenson, T & Shafran, R 2024, 'Long COVID: what do we know now and what are the challenges ahead?', Journal of the Royal Society of Medicine, vol. 117, no. 7, pp. 224-228. https://doi.org/10.1177/01410768241262661

TY - JOUR

T1 - Long COVID

T2 - what do we know now and what are the challenges ahead?

AU - Pereira, Snehal M Pinto

AU - Newlands, Fiona

AU - Anders, Jake

AU - Banerjee, Amitava

AU - Beale, Sarah

AU - Blandford, Ann

AU - Brown, Kate

AU - Bu, Feifei

AU - Fong, Wing Lam Erica

AU - Gilpin, Gina

AU - Hardelid, Pia

AU - Kovar, Jana

AU - Lim, Jason

AU - Park, Chloe

AU - Raveendran, Vishnuga

AU - Shah, Anoop D

AU - Shao, Xin

AU - Wong, Andrew

AU - Stephenson, Terence

AU - Shafran, Roz

PY - 2024/7/30

Y1 - 2024/7/30

N2 - The first case of severe acute respiratory syndrome coronavirus 2 was reported in Wuhan, China, in December 2019; the first case in the UK was reported in January 2020. By March 2020, reports were emerging that some coronavirus disease 2019 (COVID-19) survivors were left with persisting health problems rather than making a complete recovery. These people are commonly referred to as having Long COVID or post-COVID-19 condition. The UK government has invested over £50 million in Long COVID research1 and over 200 symptoms associated with Long COVID, in adults and in children and young people (CYP), have been identified.2,3 Yet, there is stark heterogeneity in the literature regarding the implementation of, and approach to, treating Long COVID. The purpose of this commentary is to reflect on what we know and what we need to know about Long COVID and to provide a springboard for suggestions on how to be better prepared for future pandemics.

AB - The first case of severe acute respiratory syndrome coronavirus 2 was reported in Wuhan, China, in December 2019; the first case in the UK was reported in January 2020. By March 2020, reports were emerging that some coronavirus disease 2019 (COVID-19) survivors were left with persisting health problems rather than making a complete recovery. These people are commonly referred to as having Long COVID or post-COVID-19 condition. The UK government has invested over £50 million in Long COVID research1 and over 200 symptoms associated with Long COVID, in adults and in children and young people (CYP), have been identified.2,3 Yet, there is stark heterogeneity in the literature regarding the implementation of, and approach to, treating Long COVID. The purpose of this commentary is to reflect on what we know and what we need to know about Long COVID and to provide a springboard for suggestions on how to be better prepared for future pandemics.

U2 - 10.1177/01410768241262661

DO - 10.1177/01410768241262661

M3 - Article

SN - 1758-1095

VL - 117

SP - 224

EP - 228

JO - Journal of the Royal Society of Medicine

JF - Journal of the Royal Society of Medicine

IS - 7

ER -

Long COVID: what do we know now and what are the challenges ahead?

Abstract

Access to Document

Fingerprint

Cite this